The HER2CLIMB-02 trial found that adding tucatinib to TDM-1 offered only a modest 2-month PFS benefit. This came at the cost of substantially increased toxicity, including transaminitis and diarrhea, suggesting the two agents are better used sequentially for most patients.

Positive data from both DESTINY-Breast09 (TDXD-based) and PATINA (CDK4/6i maintenance) create a new dilemma. With similar PFS outcomes, the first-line choice for metastatic HER2+/HR+ patients now hinges on toxicity profiles and patient preference rather than a single efficacy winner.

Unlike the standard chemotherapy regimen TCHP, the newer drug T-DXd can cross the blood-brain barrier. This is a crucial advantage for high-risk HER2-positive breast cancer patients, as it offers the potential to prevent brain metastases, a common and devastating site of recurrence for this cancer subtype.

The PATINA trial revealed palbociclib, not known for CNS activity, unexpectedly lowered the incidence of CNS progression in triple-positive metastatic breast cancer (13.8% vs 20.4%). This suggests a potential new benefit for this drug in a patient population at high risk for brain metastases.

For patients with otherwise well-controlled disease who develop isolated oligoprogression in the brain, evidence suggests a better survival outcome from adding local therapy (like SRS) and continuing the current effective systemic therapy, rather than switching the systemic regimen entirely.

Counterintuitively, adding palbociclib to maintenance therapy showed a favorable quality of life in the PATINA trial. Despite known toxicities, the drug delayed the time to first symptom progression. This suggests that the benefit of superior disease control can outweigh the negative impact of treatment side effects on patient-reported outcomes.

The COMPEL trial provides strong evidence for a "treat through progression" strategy. For patients progressing on osimertinib monotherapy, continuing the TKI while adding chemotherapy significantly reduces the probability of CNS progression, highlighting its role as a CNS protectant even when systemic efficacy is waning.

To mitigate long-term toxicity from TDXD, oncologists are proposing an "induction/maintenance" approach. Patients receive TDXD for an initial period to achieve maximal response, then switch to a less toxic maintenance regimen for a "chemotherapy holiday," improving quality of life.

Based on recent trial data, the optimal maintenance strategy for HER2+ metastatic breast cancer differs by subtype. The speaker suggests palbociclib for hormone receptor-positive patients and tucatinib for hormone receptor-negative patients, reflecting a personalized, data-driven treatment approach.